The Latest Cardiac and Vascular News
Fourth Quarter 2021 Revenue of $3.7 million, a 75% Increase Over Prior Year MINNEAPOLIS, Feb. 15, 2022 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients […]
MINNEAPOLIS, Jan. 10, 2022 (GLOBE NEWSWIRE) — CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced certain preliminary unaudited fourth quarter and full year 2021 […]
Third Quarter 2021 Revenue of $3.4 million, a 241% Increase Over Prior Year MINNEAPOLIS, Nov. 04, 2021 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive […]
MINNEAPOLIS, Sept. 17, 2021 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, today announced it will be added […]
Second Quarter 2021 Revenue of $3.1 Million, a 150% Increase Over Prior Year MINNEAPOLIS, Aug. 04, 2021 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive […]
SANTA CLARA, Calif. and DUBLIN, July 6, 2021 /PRNewswire/ — Treo Ventures portfolio company CVRx, Inc. announced the upsized pricing of its initial public offering on the Nasdaq Global Select Market. Treo led the pre-IPO round in July 2020 with Treo General Partner, Mudit K. Jain, PhD, joining […]
MINNEAPOLIS, June 29, 2021 (GLOBE NEWSWIRE) — CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, announced today the upsize and pricing of its […]
MINNEAPOLIS, June 10, 2021 (GLOBE NEWSWIRE) — CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced the completion of the first clinical procedure with the company’s new lead implantation approach. The novel […]
Paul Verrastro Named CMO and Thomas Hengsteler Named VP of European Sales and Marketing MINNEAPOLIS, Jan. 05, 2021 (GLOBE NEWSWIRE) — CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced that it […]
Incremental Reimbursement in Outpatient Setting Will Expand Availability of the Breakthrough BAROSTIM Therapy Heart Failure Treatment MINNEAPOLIS, Dec. 03, 2020 (GLOBE NEWSWIRE) — CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced […]
